Antimotility agents and F. coli infection

April 1999
CMAJ: Canadian Medical Association Journal;4/06/99, Vol. 160 Issue 7, p984
Academic Journal
No abstract available.


Related Articles

  • Antimicrobial and Antimotility Agent Use in Persons with Shiga Toxin–Producing Escherichia coli O157 Infection in FoodNet Sites. Nelson, Jennifer M.; Griffin, Patricia M.; Jones, Timothy F.; Smith, Kirk E.; Scallan, Elaine // Clinical Infectious Diseases;May2011, Vol. 52 Issue 9, p1130 

    Antimicrobial and antimotility agents are not recommended for the treatment of Shiga toxin–producing Escherichia coli O157 infection. In our study, many persons with Shiga toxin–producing E. coli O157 infection took antimicrobial (62%) and antimotility agents (32%); 43 (29%) of 146...

  • Antimotility Agents for the Treatment of Clostridium difficile Infection: Is the Juice Worth the Squeeze? Gerding, Dale N. // Clinical Infectious Diseases;3/1/2009, Vol. 48 Issue 5, p606 

    The author reflects on the relevance of antimotility agents for the treatment of clostridium difficile infection (CDI). He cites a literature case of patients treated with both antibiotics and antimotility agents. He suggests that the use of antimotility agents in the absence of treatment of CDI...

  • Antimotility Agents for the Treatment of Clostridium difficile Diarrhea and Colitis. Koo, Hoonmo L.; Koo, Diana C.; Musher, Daniel M.; DuPont, Herbert L. // Clinical Infectious Diseases;3/1/2009, Vol. 48 Issue 5, p598 

    Antimotility agent use for the treatment of Clostridium difficile infection (CDI) is discouraged. We reviewed the literature and unpublished postmarketing surveillance reports regarding antimotility treatment of CDI. Twenty reports met inclusion criteria, describing 55 patients with CDI who were...

  • Host and pathogen determinants of verocytotoxin-producing Escherichia coli-associated hemolytic uremic syndrome. Karmali, Mohamed A. // Kidney International Supplement;Feb2009, Issue 112, pS4 

    Verocytotoxin (VT)-producing Escherichia coli (VTEC) infection is associated with a spectrum of clinical manifestations that includes diarrhea, hemorrhagic colitis, and the hemolytic uremic syndrome (HUS). The occurrence of HUS in a minority of individuals in outbreaks of VTEC infection is a...

  • Management of travellers' diarrhoea. Hill, David R.; Ryan, Edward T. // BMJ: British Medical Journal (International Edition);10/11/2008, Vol. 337 Issue 7674, p863 

    The article discusses the prevention and treatment of travellers' diarrhoea. A description of travellers' diarrhoea is presented along with causes including enteric bacteria, Escherichia coli, Campylobacter, Salmonella, and Shigella. Norovirus and rotavirus are viral causes. The duration of the...

  • Shiga Toxin-Producing Escherichia coli Urinary Tract Infection Associated with Hemolytic-Uremic Syndrome in an Adult and Possible Adverse Effect of Ofloxacin Therapy. Miedouge, Marcel; Hacini, Jamale; Grimont, Francine; Watine, Joseph // Clinical Infectious Diseases;2/1/2000, Vol. 30 Issue 2, p395 

    Deals with Shiga toxin-producing Escherichia coli (E. coli) urinary tract infection associated with hemolytic-uremic syndrome (HUS). Importance of direct detection of Shiga toxins in urinary E. coli; Adverse effect of antimicrobial agents in HUS.

  • Frequency of isolation of Cryptosporidium spp. F5 Escherichia coli and Salmonella spp. in eight calves dairy farms Mitidja (Algeria). Akam, A.; Khelef, D.; Kaidi, R.; Rahal, Kh.; Tali-Maamar, H.; Mouffok, F.; Mekroud, A.; Chirilã, F. // Bulletin of the University of Agricultural Sciences & Veterinary;2009, Vol. 66 Issue 2, p66 

    352 faecal samples from calves were collected in eight Mitidja's farms in Algeria in order to appreciate feacal shedding of C. parvum, E. coli F5+ and Salmonella. The results showed that C. parvum is the most identified agent (28.9%) compared to E. coli F5+ (2.6%) and Salmonella (1.2%). The...

  • HIGHLIGHTS. Dale, David C.; Federman, Daniel D. // Cortlandt Forum;2/25/2002, Vol. 15 Issue 2, p105 

    Reports developments related to treatment of several diseases in the U.S. as of February 2002. Recommendation of graduated thresholds for tuberculosis positivity; Identification of antibacterial agents for Mycobacterial infections; Treatment of E. coli infections with antibiotics.

  • Synthesis of [F]-labelled Maltose Derivatives as PET Tracers for Imaging Bacterial Infection. Namavari, Mohammad; Gowrishankar, Gayatri; Hoehne, Aileen; Jouannot, Erwan; Gambhir, Sanjiv // Molecular Imaging & Biology;Apr2015, Vol. 17 Issue 2, p168 

    Purpose: To develop novel positron emission tomography (PET) agents for visualization and therapy monitoring of bacterial infections. Procedures: It is known that maltose and maltodextrins are energy sources for bacteria. Hence, F-labelled maltose derivatives could be a valuable tool for imaging...

  • In vitro and in vivo evaluation of [18F]ciprofloxacin for the imaging of bacterial infections with PET. Langer, Oliver; Brunner, Martin; Zeitlinger, Markus; Ziegler, Sophie; Müller, Ulrich; Dobrozemsky, Georg; Lackner, Edith; Joukhadar, Christian; Mitterhauser, Markus; Wadsak, Wolfgang; Minar, Erich; Dudczak, Robert; Kletter, Kurt; Müller, Markus // European Journal of Nuclear Medicine & Molecular Imaging;Feb2005, Vol. 32 Issue 2, p143 

    Purpose: The suitability of the 18F-labelled fluoroquinolone antibiotic ciprofloxacin ([18F]ciprofloxacin) for imaging of bacterial infections with positron emission tomography (PET) was assessed in vitro and in vivo. Methods: For the in vitro experiments, suspensions of various E. coli strains...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics